News
Novo Nordisk underestimated the impact of competition from personalized compounded drugs when providing sales estimates for ...
Thermo Fisher Scientific has implemented a string of layoffs in Carlsbad, California, in recent years, but it appears the ...
After 24 weeks of treatment, Rinvoq at two doses—15 mg and 30 mg—helped 44.6% and 54.3% of adult alopecia patients achieve 80 ...
In his first public appearance as Incyte’s CEO, Bill Meury outlined his priorities for the company, which include taking a ...
As Eli Lilly rolls ahead with a $27 billion investment to prop up four new manufacturing facilities in the U.S, the company ...
Fierce Pharma Asia—GSK's massive Hengrui deal; Takeda's revenue drop; Celltrion's major US plant buy
GSK signed a 12-asset licensing deal with Hengrui Pharma. Generic erosion on Vyvanse continued to hurt Takeda. Celltrion is ...
Nevertheless, Moderna has lowered its revenue guidance for the year by $300 million. The company now expects to generate ...
A variety of GLP-1 drugs that were developed to treat Type 2 diabetes, including Novo Nordisk’s Ozempic, have secured label ...
Merck will reduce its workforce by approximately 6,000 employees in “some areas of our global workforce,” the New Jersey ...
Merz Aesthetics has revamped its sales and marketing leadership, promoting an employee and hiring a vice president from GSK ...
Vinay Prasad, M.D., has left the FDA less than three months into the role as director of the Center for Biologics Evaluation ...
Despite efforts to spare employees by scaling back R&D and reducing operating costs by roughly $1.5 billion over the next two ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results